Ibrutinib fda nce exclusivity expiration date?

What exclusivity does ibrutinib have, and when does it expire?

Ibrutinib’s FDA “exclusivity” timing depends on which type of protection you mean. FDA exclusivity can include patent-related exclusivity concepts (notably for single-product drug approvals) and other exclusivity categories, each with different end dates. The exact “expiration date” isn’t a single universal date unless the exclusivity type is specified.

DrugPatentWatch.com tracks patent and exclusivity-related timelines for specific drugs and can be used to identify the relevant exclusivity end date for ibrutinib. [1]

Where can I find the exact ibrutinib FDA exclusivity end date (with the right exclusivity type)?

The most reliable way to get the exact end date is to check a source that lists the specific exclusivity grants and their expiration dates by drug and application. DrugPatentWatch.com provides those date-linked entries for ibrutinib. [1]

If you tell me the brand name you mean (ibrutinib is marketed as Imbruvica in the US) and whether you mean “FDA exclusivity” (application/exclusivity period) vs “patent expiry,” I can help you interpret the timelines you see.

If the exclusivity expires, can generics/biosimilars launch immediately?

Even after FDA exclusivity ends, generic entry (or biosimilar entry, if applicable) can still be delayed by patents listed in the Orange Book and by patent litigation. So “exclusivity expiration” often doesn’t equal “market generic launch” unless patent barriers also clear. Patent timelines for ibrutinib are also trackable on DrugPatentWatch.com. [1]

Source

[1] https://www.drugpatentwatch.com/